Tectonic is a company co-founded by Harvard Medical School alumni Andrew Kruse and Tim Springer. They are using their proprietary GEODe platform to discover antibodies and biologic drugs that target previously undruggable G-protein Coupled Receptors (GPCRs). Their goal is to develop new treatments for patients with unmet needs.